The short version of mass spectrometry fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-27. Anything still debated is marked as such rather than presented as settled.
Long-term storage of the dry powder is typically at minus twenty degrees Celsius or lower, protected from light and moisture. Solutions are commonly kept frozen and thawed only once, because repeated freeze-thaw cycles can promote aggregation and loss of measurable peptide content. Buffers near neutral pH are preferred over strongly acidic or strongly basic conditions. Shipping at ambient temperature is acceptable for short periods when the powder remains sealed and desiccated.
Identity and purity are assessed by complementary methods rather than a single test. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and reports a percentage purity. Mass spectrometry, most often with electrospray ionization, confirms the expected molecular mass and detects sequence-related variants. Amino acid analysis can verify composition, while water content and residual counterion measurements support the mass balance of a batch. Stability studies under accelerated conditions are used to estimate shelf life, though such estimates carry uncertainty for long-term storage.
Material supplied for research use is normally a white to off-white lyophilized powder. The solid is hygroscopic and is handled in a low-humidity environment to limit water uptake. Bulk quantities are frequently shipped in sealed vials under inert gas. Once reconstituted in water or a neutral buffer, the solution is less stable than the dry powder and is usually divided into single-use aliquots.
Verification of identity and purity relies on analytical methods used across peptide chemistry. Reverse-phase high-performance liquid chromatography separates components by hydrophobicity and provides a purity estimate. Mass spectrometry confirms molecular mass and helps detect modifications. Together these techniques give complementary information about whether a sample matches its expected structure. Results depend on method parameters and reference standards, so reported purity values are meaningful only when the analytical conditions are stated. Consistency between laboratories requires comparable protocols and well-characterized reference materials.
Peptides such as ipamorelin are subject to chemical and physical degradation. Hydrolysis of peptide bonds, oxidation of susceptible residues, and aggregation are common pathways that reduce purity over time. The rate of these processes depends on temperature, moisture, pH, and the number of freeze-thaw cycles a sample undergoes. Because the compound is typically handled as a lyophilized powder, controlling moisture during storage is a central concern. Degradation products can be detected with separation techniques that resolve the parent peptide from related impurities.
Lyophilized material is generally stored frozen and protected from light and moisture. Typical recommendations place dry powder at temperatures well below freezing, while reconstituted solutions are kept cold and used within a defined window. Repeated freezing and thawing should be avoided because it can promote aggregation and loss of material. The choice of solvent matters as well; compatibility with the intended diluent should be checked before preparation. These handling practices aim to preserve both the quantity and the integrity of the peptide.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid for research use |
| Solubility | Soluble in water and neutral buffers | Brief mixing may be needed |
| Storage temperature | -20 C or below | Desiccated, protected from light |
| Identity method | LC-MS or ESI-MS | Confirms molecular mass |
| Purity method | RP-HPLC with UV detection | Reported as percentage purity |
Storage recommendations for ipamorelin usually focus on temperature, moisture, and light. Lyophilized powder is typically held at or below minus twenty degrees Celsius in a desiccated container protected from light. Reconstituted solutions are often aliquoted and stored at minus eighty degrees Celsius to reduce repeated freeze-thaw cycles, which can promote aggregation or degradation. The optimal buffer and pH depend on the specific assay, and no single condition applies to every experimental context. Peptide stability should be assessed with time-point measurements rather than assumed from general handling rules.
In the scientific literature, ipamorelin appears mainly in preclinical studies, receptor binding assays, and reviews of growth hormone secretagogues. Authors often discuss its selectivity profile alongside limitations such as small sample sizes, short study durations, and differences between species. Some papers examine pharmacokinetics and clearance, but human data are limited and not sufficient to define general clinical effects. Regulatory discussion treats the compound as an investigational or research substance rather than an approved therapy in most jurisdictions. Open questions include oral bioavailability, long-term endocrine effects, and whether selectivity observed in animals persists in humans.
Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. The compound was designed in the 1990s during a search for agents that release growth hormone with fewer off-target hormonal effects than earlier secretagogues. It appears in the research literature under several sequence-based names. Material supplied for laboratory work is normally a lyophilized solid, and it is not marketed as an approved therapeutic in major jurisdictions.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.
November 2015 wurde die Gesellschaft in Huntsman P&A Germany GmbH umbenannt. Die Pigmentsparte von Huntsman P&A wurde 2017 in eine eigene Gesellschaft mit dem Namen Venator Materials ausgegliedert und an die Börse gebracht. Der Konzern hat heute seinen Sitz in Wynyard, Stockton-on-Tees, Vereinigtes Königreich, und beschäftigt mehr als 4.000 Mitarbeiter an 27 Produktionsstandorten. Am 19. März 2018 wurde die deutsche Gesellschaft schließlich in Venator Germany GmbH umfirmiert. Im Herbst 2025 gingen verschiedene Teile der britischen Venator-Gruppe in die Insolvenz, wovon auch der deutsche Standort in Duisburg (Venator Germany GmbH) betroffen war. Auf Beschluss des Amtsgerichts Duisburg wurde am 5. September 2025 das vorläufige Insolvenzverfahren über das Vermögen von "Venator Germany GmbH" (Standort: Duisburg) eröffnet. Mit Datum vom 1. Februar 2026 kaufte die Frankfurter ICIG Gruppe dieses Unternehmen und gliederte es unter dem neuen Namen "SACHTLEBEN Functional Additives GmbH" in die Gruppe ein. Für den Standort Uerdingen ("Venator Uerdingen GmbH", Titandioxid-Produktion; Eröffnung Insolvenzverfahren am 29. August 2025 am AG Krefeld) war zu diesem Zeitpunkt noch keine Lösung gefunden (Stand: Mitte Februar 2026).
== Standorte == SACHTLEBEN Functional Additives GmbH, Duisburg (seit 1. Februar 2026; Rechtsnachfolgerin der aufgelösten Venator Germany GmbH) Venator Uerdingen GmbH, Krefeld Venator Wasserchemie GmbH, Ibbenbüren Venator Pigments GmbH & Co. KG, Walluf
== Vertriebsbüros und Partner == Duisburg New York – Sachtleben Corporation, White Plains, Vereinigte Staaten Shanghai – Sachtleben Chemie Shanghai, Shanghai, China Helsinki – Sachtleben Chemie GmbH, Helsinki, Finnland 85 Distributionspartner weltweit
== Weblinks == Internetauftritt von Venator Beschreibung aller Standorte auf dieser Themenroute als Teil der Route der Industriekultur Frühe Dokumente und Zeitungsartikel zur Venator Germany in den Historischen Pressearchiven der ZBW
Sources: de.wikipedia.org
Dry powder is held at minus twenty degrees Celsius or colder, away from light and moisture. Sealed vials under inert gas limit degradation during storage.
Each cycle can cause aggregation and adsorption losses that lower measured peptide content. Dividing a solution into single-use aliquots reduces this risk.
Reversed-phase chromatography reports purity, while mass spectrometry confirms identity through molecular mass. Amino acid analysis adds composition data.
Dry powder is typically kept frozen, desiccated, and protected from light. Avoiding moisture exposure and large temperature swings helps slow degradation. Storage recommendations vary by supplier and should be followed for the specific material.